Overall, our findings demonstrate that the B1R agonist NG29 can be administered i.a. and i.v. in dosages that create preferential extensive extravasation of various drugs in the glioma microenvironment (including central and peripheral portions) while not disturbing the integrity of normal microvessels of organs, such as the normal brain, lung, pancreas, kidney, muscle, skin, heart, liver, and of macrovessels (aortae) (Figure 6). This evidence concerns the gene BDKRB1 and central nervous system cancer.